Medicine and Dentistry
Observational Study
100%
Multiple Myeloma
100%
Dendritic Cell
100%
Lenalidomide
50%
Bortezomib
37%
Progression Free Survival
37%
Overall Survival
37%
M Protein
25%
Adverse Event
25%
Immunogenicity
22%
Bone Lesion
12%
Biochemical Recurrence
12%
Neutropenia
12%
Carfilzomib
12%
Immunoglobulin A
12%
Treatment Withdrawal
12%
Time to Treatment
12%
Proteasome Inhibitor
12%
Daratumumab
12%
Population Research
12%
Retrospective Study
12%
Cancer Therapy
12%
Cancer Research
12%
Kaplan Meier Method
12%
Biological Marker
12%
Symptomatic Treatment
12%
Immunoglobulin
12%
Anemia
12%
Survival Time
12%
Doxorubicin
11%
Immunotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Observational Study
100%
Lenalidomide
50%
Progression Free Survival
37%
Bortezomib
37%
Overall Survival
37%
Flow Cytometry
33%
Immunogenic Cell Death
33%
M Protein
25%
Adverse Event
25%
Malignant Neoplasm
25%
Autoantigen
16%
Cyclophosphamide
16%
Doxorubicin
16%
Preclinical Study
16%
Immunoglobulin
12%
Immunoglobulin A
12%
Bone Lesion
12%
Anemia
12%
Carfilzomib
12%
Daratumumab
12%
Neutropenia
12%
Proteasome Inhibitor
12%
Survival Time
12%
Biochemical Recurrence
12%
Biological Marker
12%
Retrospective Study
12%
Population Study
12%
Immunology and Microbiology
Multiple Myeloma
100%
Arm
100%
T Cell
100%
Lenalidomide
50%
Progression Free Survival
37%
Overall Survival
37%
Cell Death
22%
Immunoglobulin Blood Level
12%
Daratumumab
12%
Survival Time
12%
Population Research
12%
Proteasome
12%
Immunoglobulin A
12%
Animal Experiment
11%
Functional Status
11%
Preclinical Study
11%
Vaccine Immunogenicity
11%
Autoantigen
11%
Immunotherapy
11%
Cyclophosphamide
11%